Cover Image
市場調查報告書

尿失禁:開發中產品分析

Urinary Incontinence - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232798
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
尿失禁:開發中產品分析 Urinary Incontinence - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 81 Pages
簡介

尿失禁是由於膀胱失去控制造成的狀態。尿失禁的症狀有緊張性尿失禁,皮疹和其他皮膚疾病,高齡化,過重,抽煙,腎臟疾病等是可能發病的要素。主要尿失禁治療藥有抗膽鹼促效劑,局部雌激素等。

本報告提供尿失禁治療藥的開發趨勢調查,提供您開發平台各階段的產品概要,主要企業藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

尿失禁概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

尿失禁:企業開發中的治療藥

尿失禁:大學/機關研究中的治療藥

尿失禁:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

尿失禁:企業開發中的產品

尿失禁:大學/機關研究中的產品

尿失禁治療藥的開發企業

  • Allergan Plc
  • Astellas Pharma Inc.
  • Celogos
  • Cook MyoSite Incorporated
  • Evotec AG
  • FemmePharma Global Healthcare, Inc.
  • Innovacell Biotechnologie AG
  • TheraVida, Inc.

尿失禁:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (mirabegron + solifenacin succinate)
  • ASP-2205
  • ASP-5633
  • Cell Therapy for Urinary Incontinence
  • ICES-13
  • oxybutynin hydrochloride
  • Prof-003
  • RCD-1
  • senrebotase
  • Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence
  • Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases
  • THVD-201
  • THVD-202

尿失禁:最近的開發平台趨勢

尿失禁:暫停中的計劃

尿失禁:開發中止的產品

尿失禁:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8272IDB

Summary

Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H2 2016', provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
  • The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
  • The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Urinary Incontinence

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Urinary Incontinence Overview
    • Therapeutics Development
  • Pipeline Products for Urinary Incontinence - Overview
  • Pipeline Products for Urinary Incontinence - Comparative Analysis
  • Urinary Incontinence - Therapeutics under Development by Companies
  • Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes
  • Urinary Incontinence - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Urinary Incontinence - Products under Development by Companies
  • Urinary Incontinence - Products under Investigation by Universities/Institutes
  • Urinary Incontinence - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Celogos
    • Cook MyoSite Incorporated
    • FemmePharma Global Healthcare, Inc.
    • GTx, Inc.
    • Innovacell Biotechnologie AG
    • Ipsen S.A.
    • Outpost Medicine Limited
    • Taiho Pharmaceutical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • TheraVida, Inc.
  • Urinary Incontinence - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (mirabegron + solifenacin succinate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-2205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Urinary Incontinence - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enobosarm - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gtx-027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICES-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OP-233 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxybutynin chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Prof-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCD-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THVD-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THVD-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Urinary Incontinence - Dormant Projects
  • Urinary Incontinence - Discontinued Products
  • Urinary Incontinence - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
      • Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
      • Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
      • Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
      • May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
      • Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
      • Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence
      • Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
      • Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
      • Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
      • Aug 30, 2011: Innovacell passes a further milestone
      • May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence
      • Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201
      • Feb 22, 2011: Innovacell makes further progress on product development
      • Jun 28, 2010: Astellas and Teva reached a Settlement Agreement on VESIcare Patent Case
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Urinary Incontinence, H2 2016
  • Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2016
  • Urinary Incontinence - Pipeline by Celogos, H2 2016
  • Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2016
  • Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016
  • Urinary Incontinence - Pipeline by GTx, Inc., H2 2016
  • Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2016
  • Urinary Incontinence - Pipeline by Ipsen S.A., H2 2016
  • Urinary Incontinence - Pipeline by Outpost Medicine Limited, H2 2016
  • Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Urinary Incontinence - Dormant Projects, H2 2016
  • Urinary Incontinence - Dormant Projects (Contd..1), H2 2016
  • Urinary Incontinence - Dormant Projects (Contd..2), H2 2016
  • Urinary Incontinence - Discontinued Products, H2 2016
  • Urinary Incontinence - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Urinary Incontinence, H2 2016
  • Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top